Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2016.03.105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Localized inflammation in dengue vaccine-induced skin rash is not associated with continuous presence of dengue virus genome.
J Invest Dermatol
December 2024
Department of Microbiology and Molecular Genetics and Vaccine Testing Center, Larner College of Medicine, University of Vermont, Burlington, VT, USA. Electronic address:
Vaccination with the tetravalent live attenuated dengue virus (DENV) vaccines TV003 and TV005 causes a mild, relatively localized erythematous maculopapular skin rash in most dengue-naïve vaccinees. Human challenge model DENV strains, DENV2Δ30 and DENV3Δ30, trigger a confluent skin rash over most of the body in most unvaccinated participants. To determine the etiology of these rashes we performed in situ hybridization for DENV genome and assessed cellular infiltration by hematoxylin/eosin staining in skin biopsies from humans infected with live attenuated dengue vaccine DENV2Δ30 or DENV3Δ30 challenge strains.
View Article and Find Full Text PDFDengue virus: Etiology, epidemiology, pathobiology, and developments in diagnosis and control - A comprehensive review.
Infect Genet Evol
December 2024
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Dengue flavivirus (DENV) is the virus that causes dengue, one of the most dangerous and common viral diseases in humans that are carried by mosquitoes and can lead to fatalities. Every year, there are over 400 million cases of dengue fever worldwide, and 22,000 fatalities. It has been documented in tropical and subtropical climates in over 100 nations.
View Article and Find Full Text PDFFatal dengue virus infection in an unvaccinated traveler.
Eur J Clin Microbiol Infect Dis
December 2024
Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Dengue is an increasing threat to individuals living in or visiting endemic countries. Effective vaccines have become available, but their use in travelers is typically only recommended to individuals with documented prior infection. We present a fatal case of severe dengue in an unvaccinated traveler without known prior dengue virus infection but longitudinal serologic and molecular evidence for secondary infection.
View Article and Find Full Text PDFNew dengue vaccine for UK travellers: recommended only for those with a previous infection.
Lancet Microbe
December 2024
Department of Virology, University College London Hospitals, London, UK; Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, UK.
Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study.
Lancet Microbe
December 2024
Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address:
Background: Serology for dengue viruses (DENV) and Zika virus (ZIKV) has been hindered by antibody cross-reactivity, which limits the utility of these tests for surveillance and assessment of sero-status. Our aim was to develop a multiplexed IgG-based assay with increased accuracy to assess the history of previous DENV and ZIKV infections.
Methods: We developed and assessed the analytical performance of a sample-sparing, multiplexed, microsphere-based serological assay using domain III of the envelope protein (EDIII) of DENV serotypes 1-4 and ZIKV, the most variable region between each virus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!